TABLE 1.
Study Demographics
| Osteosarcoma (n=15) | Wilms (n=3) | Neuroblastoma (n=5) | Wilms + Neuroblastoma (n=8) | Osteosarcoma vs Wilms + NB | |
|---|---|---|---|---|---|
| Total number of patients | 2813 | 560 | 1409 | 1969 | |
|
| |||||
| Age of participants (95% CI) | 13.5 (12.9–14.1) | 3.55 (3.9–4.1) | 4.28 (0.01–8.65) | 4.00 (1.54–6.69) | p <0.0001 (7.34–11.6) |
|
| |||||
| Female % (95% CI) | 41.5 (36.4–46.6) | 51.6 (47.0–57.0) | 37.8 (25.0–50.6) | 42.4 (33.0–51.9) | p = 0.861 (−11.7–9.85) |
|
| |||||
| Cumulative dose [range] | 375 [125–600] | 267 [250–301] | 167 [35–330] | 197 [35–330] | p = 0.0016 (74.74–283.0) |
|
| |||||
| Dexrazoxane (# of studies) | 4 | 0 | 1 | 1 | |
|
| |||||
| Cardiotoxicity % (95% CI) [range] | 10.02 (4.57–15.47) [0–33.3%] | 1.61 (0.44–2.78) [1.3–2.1] | 0.64 (−0.5–1.8) [0.0–2.8] | 0.962 (0.002–0.017) [0.0–2.8] | p = 0.047 (0.1088–18.01) |
|
| |||||
| All cardiac abnormalities % (95% CI) [range] | 17.72 (7.14–28.3) [0–74.8%] | 2.83 (−3.8–9.4) [1.2–5.9] | 0.64 (−0.5–1..8) [0.0–2.8] | 1.23 (0.0–2.6) [0.0–5.9] | p = 0.062 (−0.86–33.8) |
|
| |||||
| 5 year survival (95% CI) [range] | 78.43 (74.9–81.9) [74–95.1] | 96.5† | 65.6 (43.7–87.5) [26–94.9] | 70.0 (52.9–87.1) [26–94.9] | p = 0.225 (−5.52–22.3) |
|
| |||||
| Follow-up time in years (95% CI) | 6.44 (3.97–8.91) | 4.13 (2.86–5.41) | 5.23 (3.33–7.14) | 4.87 (3.6–6.13) | p = 0.443 (−2.58–5.73) |
| Additional treatment modalities # of studies) | |||||
| Radiation | 3 | 2 | 2 | 4 | |
| Additional Chemotherapeutics | ‡ | ‡ | ‡ | ||
| Topoisomerase inhibitors | 4 | 2 | 4 | 6 | |
| Alkylating agents | 14 | 1 | 5 | 6 | |
| Vinca alkaloids | 0 | 2 | 2 | 4 | |
| Antimetabolites | 10 | 0 | 1 | 1 | |
†
two studies not reporting survival data
‡
one study not reporting concurrent chemotherapeutic agents